Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04543188
Recruitment Status : Not yet recruiting
First Posted : September 10, 2020
Last Update Posted : September 10, 2020
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
First-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF V600-mutated advanced solid tumor malignancies with and without brain involvement.

Condition or disease Intervention/treatment Phase
Malignant Melanoma Carcinoma, Non-Small-Cell Lung Brain Neoplasms, Primary Brain Neoplasms Malignant Neoplasms Drug: PF-07284890 Drug: Binimetinib Drug: Midazolam Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 225 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A TWO-PART, PHASE 1A/B, OPEN-LABEL, MULTICENTER TRIAL EVALUATING PHARMACOKINETICS, SAFETY AND EFFICACY OF PF 07284890 (ARRY 461) IN PARTICIPANTS WITH BRAF V600 MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT
Estimated Study Start Date : September 25, 2020
Estimated Primary Completion Date : May 10, 2023
Estimated Study Completion Date : May 10, 2023

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
Drug Information available for: Midazolam

Arm Intervention/treatment
Experimental: PF-07284890 (Part A monotherapy)
Monotherapy dose escalation of PF-07284890
Drug: PF-07284890
PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)
Other Name: ARRY-461

Experimental: PF-07284890+binimetinib (Part A combo-therapy)
Combination dose escalation of PF-07284890 + binimetinib
Drug: PF-07284890
PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)
Other Name: ARRY-461

Drug: Binimetinib
Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily
Other Name: Mektovi

Experimental: Expansion Phase (Part B, Cohort 1)
PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma or Non-Small Cell Lung Cancer (NSCLC), with asymptomatic brain involvement, and no prior BRAF or MEK inhibitor utilization
Drug: PF-07284890
PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)
Other Name: ARRY-461

Drug: Binimetinib
Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily
Other Name: Mektovi

Experimental: Expansion Phase (Part B, Cohort 2)
PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma or NSCLC, with symptomatic brain involvement, and no prior BRAF or MEK inhibitor utilization
Drug: PF-07284890
PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)
Other Name: ARRY-461

Drug: Binimetinib
Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily
Other Name: Mektovi

Experimental: Expansion Phase (Part B, Cohort 3)
PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma or NSCLC, with asymptomatic brain involvement, and prior BRAF inhibitor utilization
Drug: PF-07284890
PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)
Other Name: ARRY-461

Drug: Binimetinib
Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily
Other Name: Mektovi

Experimental: Expansion Phase (Part B, Cohort 4)
PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 melanoma or NSCLC, with symptomatic brain involvement, and prior BRAF inhibitor utilization
Drug: PF-07284890
PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)
Other Name: ARRY-461

Drug: Binimetinib
Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily
Other Name: Mektovi

Experimental: Expansion Phase (Part B Cohort 5)
PF-07284890 (at recommended dose from Part A) plus binimetinib in participants with BRAF V600 solid tumor; history of or current leptomeningeal metastases; without disease in the brain; with disease in the brain that does not meet Cohorts 1-4; asymptomatic or symptomatic in the brain; primary brain tumors
Drug: PF-07284890
PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)
Other Name: ARRY-461

Drug: Binimetinib
Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily
Other Name: Mektovi

Experimental: Drug-Drug Interaction Substudy
PF-07284890 (at recommended dose from Part A) plus binimetinib plus midazolam in participants with BRAF V600 solid tumor
Drug: PF-07284890
PF-07284890 will be administered orally, daily for 21 consecutive days (21-day cycle)
Other Name: ARRY-461

Drug: Binimetinib
Binimetinib will be administered together with PF-07284890 orally, 45mg twice daily
Other Name: Mektovi

Drug: Midazolam
Midazolam will be administered 7 days before start of study drug, on Cycle 1 Day 1, and on Cycle 1 Day 15




Primary Outcome Measures :
  1. Phase 1a - Number of participants with dose limiting toxicities (DLTs) [ Time Frame: Cycle 1 (approximately 21 days / 3 weeks) ]
    DLTs will be evaluated during the first cycle (21 days) as both a single agent or in combination with binimetinib. The number of DLTs will be used to determine the maximum tolerated dose (MTD)/recommended dose for further study

  2. Phase 1a - Number of participants with treatment emergent adverse events (AEs) [ Time Frame: Baseline up to 30 days after last dose of study medication ]
    AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy

  3. Phase 1a - Number of participants with clinically significant change from baseline in laboratory abnormalities [ Time Frame: Baseline up to follow up visit (30 days after last dose of study treatment) ]
    Laboratory abnormalities as characterized by type, frequency, severity, and timing

  4. Phase 1a - Number of dose interruptions, dose modifications, and discontinuations due to AEs [ Time Frame: Baseline through approximately 12 months ]
    Incidence of dose interruptions, dose modifications, and discontinuations due to AEs

  5. Phase 1b - Overall response [ Time Frame: Baseline up to approximately 12 months ]
    Response will be evaluated via radiographical tumor assessments by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and intracranial response by modified RECIST version 1.1 (mRECIST v 1.1)


Secondary Outcome Measures :
  1. Phase 1a: Maximum plasma concentration of PF-07284890 and binimetinib [ Time Frame: Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8, and 24 hours (Day 2) post dose); Cycle 1 Day 15 (predose, 1, 2, 4, 6, and 8 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); End of Treatment (EOT) ]
    Single dose (Cmax) and multiple dose (assuming steady state is achieved; Css,max) pharmacokinetic (PK) parameters

  2. Phase 1a: Time to reach maximum plasma concentration of PF-07284890 and binimetinib [ Time Frame: Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8, and 24 hours (Day 2) post dose); Cycle 1 Day 15 (predose, 1, 2, 4, 6, and 8 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT ]
    Single dose (Tmax) and multiple dose (assuming steady state is achieved; Tss,max) PK parameters

  3. Phase 1a: Area under the plasma concentration-time curve from time 0 to the last time point of quantifiable concentration (AUClast) of PF-07284890 and binimetinib [ Time Frame: Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8, and 24 hours (Day 2) post dose); Cycle 1 Day 15 (predose, 1, 2, 4, 6, and 8 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT ]
    Single dose PK parameter

  4. Phase 1a: Terminal half-life (t1/2) of PF-07284890 and binimetinib [ Time Frame: Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8, and 24 hours (Day 2) post dose); Cycle 1 Day 15 (predose, 1, 2, 4, 6, and 8 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT ]
    Single dose and multiple dose (assuming steady state is achieved and data permit) PK parameter

  5. Phase 1a: Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUCinf) of PF-07284890 and binimetinib [ Time Frame: Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8, and 24 hours (Day 2) post dose); Cycle 1 Day 15 (predose, 1, 2, 4, 6, and 8 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT ]
    Single dose will be calculated as data permit PK parameter

  6. Phase 1a: Apparent oral clearance of PF-07284890 and binimetinib [ Time Frame: Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8, and 24 hours (Day 2) post dose); Cycle 1 Day 15 (predose, 1, 2, 4, 6, and 8 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT ]
    Single dose (CL/F) and multiple dose (assuming steady state is achieved and as data permit; CLss/F) PK parameter

  7. Phase 1a: Volume of distribution of PF-07284890 and binimetinib [ Time Frame: Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8, and 24 hours (Day 2) post dose); Cycle 1 Day 15 (predose, 1, 2, 4, 6, and 8 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT ]
    Single dose (Vz/F) and multiple dose (assuming steady state is achieved and as data permit; Vss/F) PK parameter

  8. Phase 1a: Area under the plasma concentration-time curve over the dosing interval at steady state (AUCss,T) of PF-07284890 and binimetinib [ Time Frame: Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8, and 24 hours (Day 2) post dose); Cycle 1 Day 15 (predose, 1, 2, 4, 6, and 8 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT ]
    Multiple dose (assuming steady state is achieved) PK parameter

  9. Phase 1a: Trough plasma concentration at steady state (Css,min) of PF-07284890 and binimetinib [ Time Frame: Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8, and 24 hours (Day 2) post dose); Cycle 1 Day 15 (predose, 1, 2, 4, 6, and 8 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT ]
    Multiple dose (assuming steady state is achieved) PK parameter

  10. Phase 1a: Accumulation ratio (Rac) of PF-07284890 and binimetinib [ Time Frame: Cycle 1 Day 1 (predose, 1, 2, 4, 6, 8, and 24 hours (Day 2) post dose); Cycle 1 Day 15 (predose, 1, 2, 4, 6, and 8 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT ]
    Multiple dose (assuming steady state is achieved and as data permit) PK parameter

  11. Phase 1a: Overall response [ Time Frame: Baseline up to approximately 12 months ]
    Response will be evaluated via radiographical tumor assessments by RECIST v1.1 and intracranial response by mRECIST v 1.1

  12. Phase 1b - Number of patients with treatment emergent AEs [ Time Frame: Baseline up to 30 days after last dose of study medication ]
    AEs as characterized by type, frequency, severity, timing, seriousness, and relationship to study therapy

  13. Phase 1b - Number of participants with clinically significant change from baseline in laboratory abnormalities [ Time Frame: Baseline up to follow up visit (30 days after last dose of study treatment) ]
    Laboratory abnormalities as characterized by type, frequency, severity, and timing

  14. Phase 1b - Number of dose interruptions, dose modifications, and discontinuations due to AEs [ Time Frame: Baseline through approximately 12 months ]
    Incidence of dose interruptions, dose modifications, and discontinuations due to AEs

  15. Phase 1b: Maximum plasma concentration of PF-07284890 and binimetinib [ Time Frame: Cycle 1 Day 1 and 15 (predose, 1, 2, and 4 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT ]
    Single dose (Cmax) and multiple dose (assuming steady state is achieved; Css,max) PK parameter

  16. Phase 1b: Time to reach maximum plasma concentration of PF-07284890 and binimetinib [ Time Frame: Cycle 1 Day 1 and 15 (predose, 1, 2, and 4 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT ]
    Single dose (Tmax) and multiple dose (assuming steady state is achieved; Tss,max) PK parameter

  17. Phase 1b: Area under the plasma concentration-time curve from time 0 to the last time point of quantifiable concentration (AUClast) of PF-07284890 and binimetinib [ Time Frame: Cycle 1 Day 1 and 15 (predose, 1, 2, and 4 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT ]
    Single dose PK parameter

  18. Phase 1b: Terminal half-life (t1/2) of PF-07284890 and binimetinib [ Time Frame: Cycle 1 Day 1 and 15 (predose, 1, 2, and 4 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT ]
    Single dose and multiple dose (assuming steady state is achieved and data permit) PK parameter

  19. Phase 1b: Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUCinf) of PF-07284890 and binimetinib [ Time Frame: Cycle 1 Day 1 and 15 (predose, 1, 2, and 4 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT ]
    Single dose will be calculated as data permit PK parameter

  20. Phase 1b: Apparent oral clearance of PF-07284890 and binimetinib [ Time Frame: Cycle 1 Day 1 and 15 (predose, 1, 2, and 4 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT ]
    Single dose (CL/F) and multiple dose (assuming steady state is achieved and as data permit; CLss/F) PK parameter

  21. Phase 1b: Volume of distribution of PF-07284890 and binimetinib [ Time Frame: Cycle 1 Day 1 and 15 (predose, 1, 2, and 4 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT ]
    Single dose (Vz/F) and multiple dose (assuming steady state is achieved and as data permit; Vss/F) PK parameter

  22. Phase 1b: Area under the plasma concentration-time curve over the dosing interval at steady state (AUCss,T) of PF-07284890 and binimetinib [ Time Frame: Cycle 1 Day 1 and 15 (predose, 1, 2, and 4 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT ]
    Multiple dose (assuming steady state is achieved) PK parameter

  23. Phase 1b: Trough plasma concentration at steady state (Css,min) of PF-07284890 and binimetinib [ Time Frame: Cycle 1 Day 1 and 15 (predose, 1, 2, and 4 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT ]
    Multiple dose (assuming steady state is achieved) PK parameter

  24. Phase 1b: Accumulation ration (Rac) of PF-07284890 and binimetinib [ Time Frame: Cycle 1 Day 1 and 15 (predose, 1, 2, and 4 hours post dose); Cycles 2-6 Day 1 (predose and 2 hours post dose); EOT ]
    Multiple dose (assuming steady state is achieved and as data permit) PK parameter

  25. Phase 1b: Disease Control Rate (DCR) [ Time Frame: Every 6 weeks from time of enrollment up to 1 year, then every 12 weeks thereafter ]
    DCR is defined as the percent of participants with a confirmed complete response (CR), partial response (PR) or stable disease (SD) according to RECIST 1.1, at 6 weeks for both overall and intracranial

  26. Phase 1b: Progression Free Survival (PFS) [ Time Frame: Baseline to measured progressive disease (up to 12 months) ]
    The period from study entry until disease progression, death or date of last contact for both overall and intracranial.

  27. Phase 1b: Overall Survival (OS) [ Time Frame: Baseline to date of death from any cause (up to 12 months) ]
    Overall survival was the duration from enrollment to death. For participants who are alive, overall survival was censored at the last contact.

  28. Phase 1b: Duration of Response (DoR) [ Time Frame: Baseline, every 6 weeks until disease progression or unacceptable toxicity up to 1 year, then every 12 weeks thereafter ]
    Duration of response (DR) defined as time from start of first documented objective tumor response [Complete Response (CR) or Partial Response (PR)] to first documented objective tumor progression or death due to any cause, whichever occurs first.

  29. Phase 1b: Time to Tumor Response (TTR) [ Time Frame: Every 6 weeks from the time of enrollment up to 12 months ]
    TTR is defined as the time from first dose to first documentation of objective tumor response (CR or PR). For participants whose objective response (OR) proceeds from PR to CR, the onset of PR is taken as the onset of response. TTR will only be calculated for the subgroup of participants with a confirmed objective tumor response for both overall and intracranial

  30. Phase 1b: Maximum plasma concentration (Cmax) of CYP34A probe substrate midazolam [ Time Frame: Day -7 (Lead-in); Cycle 1 Day 1 and Day 15 (predose, 0.5, 1, 2, 4, and 8 hours post dose) ]
    PK parameter

  31. Phase 1b: Time to reach maximum plasma concentration (Tmax) of CYP3A4 probe substrate midazolam [ Time Frame: Day -7 (Lead-in); Cycle 1 Day 1 and Day 15 (predose, 0.5, 1, 2, 4, and 8 hours post dose) ]
    PK parameter

  32. Phase 1b: Area under the plasma concentration-time curve from time 0 to the last time point of quantifiable concentration (AUClast) of CYP3A4 probe substrate midazolam [ Time Frame: Day -7 (Lead-in); Cycle 1 Day 1 and Day 15 (predose, 0.5, 1, 2, 4, and 8 hours post dose) ]
    PK parameter

  33. Phase 1b: Terminal half-life (t1/2) of CYP3A4 probe substrate midazolam [ Time Frame: Day -7 (Lead-in); Cycle 1 Day 1 and Day 15 (predose, 0.5, 1, 2, 4, and 8 hours post dose) ]
    PK parameter as data permit

  34. Phase 1b: Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUCinf) of CYP3A4 probe substrate midazolam [ Time Frame: Day -7 (Lead-in); Cycle 1 Day 1 and Day 15 (predose, 0.5, 1, 2, 4, and 8 hours post dose) ]
    PK parameter as data permit

  35. Phase 1a: Apparent oral clearance (CL/F) of CYP3A4 probe substrate midazolam [ Time Frame: Day -7 (Lead-in); Cycle 1 Day 1 and Day 15 (predose, 0.5, 1, 2, 4, and 8 hours post dose) ]
    PK parameter as data permit

  36. Phase 1a: Volume of distribution (Vz/F) of CYP3A4 probe substrate midazolam [ Time Frame: Day -7 (Lead-in); Cycle 1 Day 1 and Day 15 (predose, 0.5, 1, 2, 4, and 8 hours post dose) ]
    PK parameter as data permit



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥18 years at the time of consent
  • Histologically confirmed diagnosis of advanced/metastatic solid tumor including primary brain tumor
  • Documented evidence of a BRAF V600 mutation in tumor tissue or blood
  • Confirmation of availability of adequate tumor tissue for submission to the sponsor/central laboratory
  • Presence or absence of brain involvement unless specified below
  • Dose Expansion (Part B)

    • Cohort 1, 2, 3, 4: melanoma or NSCLC with at least 1 parenchymal brain lesion
    • Cohort 1,3: asymptomatic in the brain for at least 14 days prior to start of study treatment
    • Cohort 2,4: symptomatic in the brain within 14 days prior to the start of study treatment
    • Cohort 5: any solid tumor that does not meet requirements for Cohorts 1-4, history of or current leptomeningeal metastases.
    • Cohort 6 (DDI Sub-study): if brain involvement present, must be asymptomatic
  • Disease progression despite prior treatment and no acceptable alternative treatment options available unless specified below
  • Dose Expansion (Part B)

    • Cohort 1, 2: No prior BRAF inhibitor in the metastatic setting or in the adjuvant setting within 6 months of study treatment
    • Cohort 3, 4: Required prior BRAF inhibitor in the metastatic setting or in the adjuvant setting within 6 months of treatment
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

Exclusion Criteria:

  • Brain metastasis/primary brain tumor requiring immediate local intervention
  • History of or current leptomeningeal metastases
  • Any other active malignancy within 2 years prior to enrollment
  • Radiation therapy to visceral metastases within 14 days prior to study treatment. WBRT within 28 days prior to study treatment.
  • Systemic anti-cancer therapy or small-molecular therapeutic(s) within 2 weeks prior to start of study treatment; Antibody based agents within 4 weeks prior to start of study treatment.
  • History or current evidence of RVO or current risk factors for RVO; History of retinal degenerative disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04543188


Contacts
Layout table for location contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com

Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT04543188    
Other Study ID Numbers: C4471001
First Posted: September 10, 2020    Key Record Dates
Last Update Posted: September 10, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pfizer:
Proto-Oncogene Proteins B-raf
Brain Neoplasms
Melanoma
Carcinoma, Non-Small-Cell Lung
Brain Diseases
Central Nervous System Neoplasms
Lung Neoplasms
Lung Diseases
Enzyme Inhibitors
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Melanoma
Carcinoma, Non-Small-Cell Lung
Brain Neoplasms
Neoplasms by Histologic Type
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Nevi and Melanomas
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Central Nervous System Neoplasms
Nervous System Neoplasms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Midazolam
Adjuvants, Anesthesia
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Anti-Anxiety Agents
Tranquilizing Agents